国家将数字化、网络化、智能化和绿色化写入制造业发展主线，把智能工厂、灯塔工厂视为新质生产力 与先进制造业集群的重要载体，并设定智能制造示范工厂数量、企业数字化水平等量化目标;地方层面 以资金补贴、试点示范、产业基金等方式，对智能工厂、灯塔工厂进行梯度培育，形成从诊断、技改到 示范工厂的完整政策链条。行业布局上，我国灯塔工厂行业布局向高技术领域延伸，核心经营指标显著 领先全球平均水平。空间布局上，我国灯塔工厂呈"沿海集聚、内陆追赶"趋势。在"人工智能+"行动 和"十五五"规划共同牵引下，AI+制造被上升为国家级系统工程，灯塔工厂向数智化、绿色化、融合化 升级，从数量领先走向区域集群和全球复制的新阶段。 本土工业软硬件厂商共振，构筑灯塔工厂数智底座 本土企业以工业软件、自动化控制、工业互联网和AI大模型为核心抓手，在感知、控制、平台与应用 多层协同发力，为灯塔工厂提供从"工厂操作系统"到场景化解决方案的全栈能力。 风险提示：政策及评选口径不及预期、技术演进与落地成效不及预期、客户集中与行业周期波动风险 智通财经APP获悉，国泰海通发布研报称，在AI与"十五五"规划双重牵引下，灯塔工厂已演进为承载新 质生产力与新型 ...

Core Viewpoint - The report from Guotai Junan emphasizes a positive outlook for the Chinese market despite recent volatility, suggesting that the market is entering a favorable phase for investment as it approaches a critical window of policy and liquidity support from December to February [1][2]. Market Analysis - The Chinese stock market has experienced significant declines, with the ChiNext index down 12%, the STAR 50 index nearly 20%, and the Hang Seng Tech index down 22%, indicating that the market has already released much of its risk [1]. - The report highlights that the current pessimism among investors is driven by year-end profit protection, reduced positions, and external factors such as the cooling of Fed rate cut expectations and increased volatility in U.S. markets [1][2]. Investment Strategy - Guotai Junan recommends increasing exposure to the Chinese market, particularly in technology, financial services, and consumer sectors, as the market is expected to stabilize and embark on a rally [1][3]. - Specific sectors to focus on include: - **Technology**: Growth in AI applications and infrastructure, with recommendations for internet, media, computing, and manufacturing sectors [3]. - **Financial Services**: Anticipated reforms in the capital market and early bank dividends, with a focus on brokerage and insurance stocks [3]. - **Consumer Goods**: Opportunities in low-priced, low-inventory consumer stocks, particularly in food, beverages, and tourism sectors, as macroeconomic risks decrease [3]. Future Outlook - The Chinese capital market is positioned for significant growth, with expectations of double-digit profit growth in non-financial sectors by 2026, driven by improved cash flows and reduced debt [2]. - The report suggests that the historical "guaranteed return" mindset is shifting, leading to increased asset management demand and a potential influx of new capital into the market [2].

二 〇 二 五 年 度 2025 年 11 月 23 日 生猪：供应增量预期显现，近端期现共振下行 | 周小球 | 投资咨询从业资格号：Z0001891 | zhouxiaoqiu@gtht.com | | --- | --- | --- | | 吴昊 | 投资咨询从业资格号：Z0018592 | wuhao8@gtht.com | 报告导读： （1）本周市场回顾（11.17-11.23） 现货市场，生猪价格弱势震荡。河南 20KG 仔猪价格 20.9 元/公斤（上周 20.9 元/公斤），本周河南 生猪价格 11.73 元/公斤（上周 11.98 元/公斤），全国 50KG 二元母猪价格 1548 元/头（上周 1548 元/ 头）。供应端，周内集团企业顺势增量，部分散户仍有惜售情绪；需求端，周内降温刺激消费增量，南北 均有消费提振。根据卓创资讯数据，本周全国出栏平均体重 124.74KG（上周 124.62KG），出栏均重环比 上升 0.1%。 期货市场，生猪期货价格弱势运行。本周生猪期货 LH2601 合约最高价为 11770 元/吨，最低价为 11330 元/吨，收盘价为 11350 元/吨（上周同期 ...

Core Viewpoint - The fiscal policy for 2026 will focus on promoting stable growth, improving people's livelihoods, and managing risks under the "15th Five-Year Plan," with a projected narrow fiscal deficit rate exceeding 4% and new local special bonds around 4.6 trillion yuan [1][5][43]. Group 1: Fiscal Policy Characteristics - The core feature of China's fiscal policy in 2025 is a shift towards a "people-oriented" expenditure structure, which is reflected in the resilience of consumption and the decline in infrastructure investment since July [1][5]. - On the revenue side, there is a weak recovery in the two accounts, with tight constraints still present. The income from individual income tax and securities transactions has improved, while land transfer income has seen a narrowing decline [5][11]. - On the expenditure side, there is a moderate expansion in total fiscal spending, with a structural shift towards social welfare. The central government's financial support is increasing, but the alignment of financial resources and responsibilities still needs optimization [1][11][15]. Group 2: Key Tasks for 2026 - The fiscal policy for 2026 will focus on three key tasks: promoting the synergy between social welfare and consumption incentives, addressing the slowdown in external demand, and resolving funding constraints for infrastructure investment [1][21][22]. - Policies such as trade-in programs and childbirth subsidies are expected to continue and be enhanced, with a focus on service consumption, projecting a retail sales growth rate of around 4.5% [2][25]. Group 3: Infrastructure Investment and Debt Management - For infrastructure investment and debt management, it is essential to clarify the scale and path of debt management funding, with an estimated need for around 3 trillion yuan in special bonds for debt management and clearing overdue accounts in 2026 [3][29]. - The pressure of interest payments after debt replacement is expected to be manageable due to a low-interest environment, which will help offset the visible interest payment pressure [3][37]. - The growth rate of infrastructure investment is projected to be around 3.5% in 2026, influenced by the constraints of debt management and the pursuit of effective investment [3][41]. Group 4: Fiscal Data Projections for 2026 - The growth rate of broad fiscal spending is expected to be around 4.6%, with a narrow fiscal deficit rate still needing to exceed 4%, and new local special bonds projected at approximately 4.6 trillion yuan [5][43][49]. - The general public budget revenue growth rate is estimated at about 1%, while government fund revenue is expected to decline by around 5% [43][46].

Core Viewpoint - The Hong Kong stock market has entered a correction phase since October, primarily due to previous significant gains, tightening dollar liquidity, and a decline in expectations for Federal Reserve rate cuts. However, the ongoing AI wave and the influx of incremental capital suggest that the bull market in Hong Kong stocks is likely to continue [1][2][13]. Market Adjustment - Since the beginning of the year, the Hong Kong stock market has performed well, with the Hang Seng Index and Hang Seng Tech reaching new highs in early October. However, by mid-October, the market began to adjust, with the Hang Seng Index experiencing a maximum decline of 5.1% and Hang Seng Tech a maximum decline of 8.1% [2]. - The Hang Seng Index and Hang Seng Tech recorded maximum gains of 47% and 61% respectively this year before entering the current adjustment phase [2]. Factors Influencing the Market - The tightening of dollar liquidity and the decline in expectations for Federal Reserve rate cuts have pressured the Hong Kong stock market. The U.S. government shutdown led to a temporary halt in government spending, causing dollar liquidity to tighten [3]. - Despite the end of the government shutdown, economic data remains unclear, leading to cautious Federal Reserve rate cut decisions. The market's expectation for a 25 basis point cut in December has dropped to 40% [3]. - The significant prior gains in the Hong Kong stock market, coupled with rising concerns over AI bubbles, have created selling pressure. The Hang Seng Tech Index has seen a maximum increase of 61% this year, while the Hang Seng Biotech Index has increased by 130% [3][8]. Historical Context of Market Corrections - In bull markets, adjustments are common, categorized into small corrections (average maximum decline of about 7%) and large corrections (average maximum decline of about 17%). Small corrections typically occur due to short-term market sentiment disturbances, while large corrections are often linked to liquidity tightening or external shocks [7][8]. - Historical data shows that small corrections in the Hang Seng Index average a maximum decline of 6.5% and last about 12 trading days, while large corrections average a maximum decline of 17% and last about 53 trading days [7][8]. Future Outlook - The tightening dollar liquidity is viewed as a short-term disturbance, and the AI wave is expected to continue. The release of previously accumulated liquidity following the end of the U.S. government shutdown may support the Hong Kong stock market [13]. - Incremental capital inflows and the gathering of quality assets suggest that the bull market in Hong Kong stocks may continue. The unique characteristics of Hong Kong assets, particularly in the context of the ongoing transformation in the domestic economy, enhance their attractiveness [13][14]. - Southbound capital is expected to continue flowing into the Hong Kong market, with over 1.3 trillion yuan already invested this year. This trend is likely to be supported by institutional investors, further propelling the market upward [14].

本报讯 （记者袁传玺）天眼查App显示，近日，安徽高投国泰海通健康并购股权投资基金合伙企业（有 限合伙）成立，执行事务合伙人为君实创业投资（海南）有限公司、国泰君安创新投资有限公司，出资 额5亿元，经营范围包括以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该 基金由君实生物、安徽省中小企业发展二期基金有限公司、国泰君安创新投资有限公司等共同出资。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本次分红对象为权益登记日登记在册的本基金所有份额持有人，权益登记日为11月25日，现金红利发放 日为11月27日。选择红利再投资方式的投资者所转换的基金份额将以2025年11月25日基金份额净值为计 算基准确定再投资份额，红利再投资所转换的基金份额将于2025年11月26日直接划入其基金账户，2025 年11月27日起投资者可以查询。根据财政部、国家税务总局的财税字[2002]128号《财政部、国家税务 总局关于开放式证券投资基金有关税收问题的通知》，基金向投资者分配的基金收益，暂免征收所得 税。本基金本次分红免收分红手续费。选择红利再投资方式的投资者其红利所转换的基金份额免收申购 费用。 证券之星消息，11月22日发布《国泰海通中证1000优选股票型发起式证券投资基金分红公告》。2025年 第一次分红。公告显示，本次分红的收益分配基准日为11月11日，详细分红方案如下： | 分级基金简称 | 代码 | 基准日基金净值 (元) | | 分红方案 (元/10份) | | | --- | ...

Group 1 - The fund manager can distribute earnings based on actual conditions, with specific distribution plans to be announced, and no distribution will occur if the fund contract has been effective for less than three months [1] - Cash dividends for investors choosing this method will be transferred from the custody account on November 27, 2025 [2] - Investors applying for fund shares on the record date will not enjoy the distribution rights, while those redeeming shares on the same date will [1] Group 2 - Investors can check the fund's sales institutions on the company's official website and must confirm the correctness of the dividend method with the respective sales institutions [2] - The company provides a customer service hotline for inquiries regarding the fund [2]

Core Viewpoint - Yuan Chuang Technology Co., Ltd. has successfully registered its IPO on the Shenzhen Main Board, taking only 8 days from submission to approval, with Guotai Junan Securities as the sponsor [1] Company Overview - Yuan Chuang Technology specializes in the research, production, and sales of rubber track products, including agricultural machinery rubber tracks, engineering machinery rubber tracks, and rubber track plates [3] - The company's products are used in various tracked agricultural and engineering machinery, such as combine harvesters, excavators, loaders, and pavers, serving applications in agriculture and construction [3] Financial Performance - Revenue for the years 2022 to 2024 and the first half of 2025 is projected to be CNY 1.261 billion, CNY 1.141 billion, CNY 1.349 billion, and CNY 652 million respectively [3] - Net profit attributable to the parent company for the same periods is expected to be CNY 139 million, CNY 178 million, CNY 155 million, and CNY 74.155 million [3] Financial Metrics - As of June 30, 2025, total assets are projected to be CNY 2.040 billion, with equity attributable to shareholders at CNY 1.312 billion [4] - The company's debt-to-asset ratio is expected to be 35.68% in 2025, down from 38.09% in 2024 and 33.31% in 2023 [4] - The basic earnings per share for 2025 is projected at CNY 1.26, compared to CNY 2.63 in 2024 and CNY 3.02 in 2023 [4] IPO Fundraising - The IPO aims to raise CNY 485 million for projects including production base construction, technology center development, and working capital supplementation [4]

Core Viewpoint - The report maintains a "Buy" rating for King’s Ray Biotechnology (01548) with a target price of HKD 26.21 per share, emphasizing the company's long-term growth strategy driven by technology and global expansion [1] Group 1: Long-term Strategic Planning - The company aims to become the global leader in biopharmaceuticals (antibody drugs, gene & cell therapy) and synthetic biology services and products, with a focus on solid cash flow to support its life sciences and biopharmaceutical CRDMO foundations [1] - The long-term revenue target is set at USD 3 billion by 2035, with an operating profit margin exceeding 20% [1] Group 2: Business Growth and Market Position - The gene & plasmid business has achieved continuous growth, aiming to expand downstream applications to enhance business potential and support further growth [2] - The antibody protein business seeks to strengthen core competitiveness and achieve market leadership by exploring non-outsourcing markets and providing innovative instruments and solutions [2] - The protein antibody drug CDMO aims to capitalize on the rebound of China's biotechnology sector, accumulate more projects and capabilities, and enhance sales in Europe and the U.S. to expand high-margin revenue sources [2] Group 3: Growth Opportunities and Product Development - The company plans to integrate its business capabilities (life sciences + thriving biology) to transform mature services into one-stop solutions, accelerating productization for downstream clients [3] - Focus areas include high-margin products in enzyme preparations, such as starch sugar, alcohol, and home care, while seeking explosive industry opportunities through innovative protein/enzyme products [3] Group 4: Financial Forecast and Valuation - The company’s revenue projections for the main business segments from 2025 to 2027 are USD 939 million, USD 825 million, and USD 961 million, with year-on-year growth rates of 58%, -12%, and 16% respectively [4] - The valuation method applied is based on a PS multiple of 6 times the projected 2026 revenue, leading to a main business valuation of RMB 35.2 billion [4] - The fair value of the company's stake in Legend Biotech, a U.S.-listed company, is estimated at RMB 17 billion as of November 20, 2025 [4]